[Antitubercular chemoprevention: hepatotoxicity and therapeutic compliance].
We studied 142 patients who received antituberculous chemoprophylaxis with isoniacide. We evaluated the increase in GOT and PGT levels, observing higher than normal values in 10.56% and 21.83% of the cases, respectively. This increase was near the limit of the statistical significance with respect to sex and it was not related with previous episodes of hepatotoxicity, although it was related to age, with a lower number of hepatic disorders among the younger groups. The presence of hepatotoxicity forced us to discontinue the therapy in just 2.81% of the cases. The level of therapy compliance was 69.1% for women and 85.25% for men, being greatest in the age group below 13 years (86.89%).
Hortoneda Giménez
M
M
Area de Medicina Preventiva y Salud Pública, Facultad de Medicina, Hospital La Fe, Valencía.
Alfonso Sánchez
J L
JL
Cortés Vizcaíno
C
C
Sabater Pons
A
A
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007223:Infant; D007538:Isoniazid / Q000009:adverse effects* / Q000627:therapeutic use; D008107:Liver Diseases / Q000097:blood; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D012737:Sex Factors; D014376:Tuberculosis / Q000188:drug therapy*
D015415:Biomarkers; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D007538:Isoniazid
Quimioprofilaxis antituberculosa: hepatotoxicidad y cumplimiento terapéutico.